FDA has granted orphan drug status to Gavo-cel from TCR2 Therapeutics. The drug is intended to treat a malignancy called cholangiocarcinoma. The company plans to present the new Phase 1/2 clinical data as part of a presentation at the European Society for Medical Oncology Sept. 17.